GlassScriptPhysician profile
Sara Brown
NPI 1861145732
$874.91
in general payments reported to CMS, 2019-2025
12 companies · $571 in 2025
The $571 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.00 · 2024: $288 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $262.87 | 2024-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $157.24 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $61.12 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.02 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $54.26 | 2025 | |
| Lilly USA, LLC | $52.51 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $51.60 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $48.23 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $43.84 | 2024-2025 | Farxiga, Airsupra |
| Abbvie INC. | $34.15 | 2023-2025 | Vraylar |
| Glaxosmithkline, LLC. | $29.79 | 2025 | Penmenvy, Shingrix, Bexsero |
| Boston Scientific Corporation | $24.28 | 2025 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.